Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarlander, Maria-
dc.contributor.authorHöglinger, Marc-
dc.contributor.authorTrottmann, Maria-
dc.contributor.authorRhomberg, Birgitta-
dc.contributor.authorCaviglia, Cornelia-
dc.contributor.authorRohrbasser, Adrian-
dc.contributor.authorFrei, Christian-
dc.contributor.authorEichler, Klaus-
dc.description.abstractObjectives: Structured treatment programs have been recommended for management of patients with chronic conditions to overcome ill-coordinated care. We aimed to evaluate a disease management program (DMP) for diabetes mellitus patients in Switzerland. Methods: We performed a prospective observational study with a propensity score-matched usual care control group from a claims database. We included type-1 and type-2 diabetes patients from a primary care setting. The DMP (intervention) comprised a structured treatment approach with an individual treatment plan, treatment goals and an interprofessional team approach. Our comprehensive outcome measures included quality of life (QOL: EQ-5D-5L), pre-defined indicators for diabetes guideline adherence, number of used services and direct medical costs. We applied a difference-in-difference (DID) approach to compare DMP with usual care (follow-up 1 year). Costs were calculated with non parametric bootstrapping (2017 Swiss Francs, CHF; conversion rate to Euros: 0.85) from a third-party payer perspective (Swiss health care insurance). Results: QOL in a sub-sample of 80 patients did not change during follow-up (mean utility 0.89 at baseline and follow-up; p=0.94). Guideline adherence showed slight improvements for DMP. For example, “non-adherence” (baseline DMP: 19%) decreased in the DMP group by -3 %-points (DID; 95%-CI: -0.07 to 0.01) but not in the control group. A general trend emerged, though mostly not statistically significant, with less used services in the DMP group compared to the control group. Costs increased in both groups during follow-up, but the increase was higher in the control group (DID, mean total costs per patient per year: CHF -950.00 [95%-CI: -1959.53 to 59.56]). Such a negative difference-in-difference estimate in favor of DMP also emerged for cost sub-categories (e.g. costs for inpatient and outpatient care). Conclusions: The structured treatment program under evaluation is a promising approach to improve diabetes care in a Swiss primary care setting but more follow-up data are needed.de_CH
dc.relation.ispartofValue in Healthde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc362: Gesundheits- und Sozialdienstede_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleImpact of a diabetes disease management program on quality of care and costs : propensity score-matched real-world data from Switzerlandde_CH
dc.typeKonferenz: Sonstigesde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
zhaw.conference.detailsVirtual ISPOR Europe 2020, Online, 16-19 November 2020de_CH
zhaw.issueSupplement 2de_CH
zhaw.publication.reviewPeer review (Abstract)de_CH
zhaw.funding.zhawWissenschaftliche Begleitevaluation Disease-Management-Programm Diabetes Mellitusde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.